3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
5
Lung Neoplasms
5
Brain Neoplasms
3
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Thoracic Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma
1
Lung Diseases
1
Gastric Adenocarcinoma
1
Detection Rate of SLN ; Accuracy Rate of Lymph Node Metastasis
1
Breast Neoplasms
1
Interventions
Nivolumab
3
osimertinib
2
Pemetrexed
2
Cetuximab
2
Carboplatin
2
spartalizumab
1
napabucasin
1
guadecitabine
1
gallium 68 PSMA-11
1
ficlatuzumab
1
exemestane
1
entinostat
1
dostarlimab
1
darolutamide
1
apalutamide
1
abexinostat
1
Tyrosine Kinase Inhibitors
1
Ramucirumab
1
Radiosurgery
1
Paclitaxel
1
Leucovorin
1
Irinotecan
1
Interleukin-2
1
Indocyanine Green
1
HuMax-IL8
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms by Site
×
Indocyanine Green
×
Clear all
NCT02111824
2021-09-17
MIMIG
The Methodist Hospital Research Institute
Phase 1
Terminated
7 enrolled